Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06448754
PHASE2

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Official title: A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Key Details

Gender

All

Age Range

18 Years - 130 Years

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2024-08-27

Completion Date

2027-07-30

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DRUG

Volrustomig

Participants will receive volrustomig via intravenous (IV) infusion.

DRUG

Carboplatin

Participants will receive carboplatin via IV infusion.

DRUG

Pemetrexed

Participants will receive pemetrexed via IV infusion.

DRUG

Ramucirumab

Participants will receive ramucirumab via IV infusion.

DRUG

Paclitaxel

Participants will receive paclitaxel via IV infusion.

Locations (77)

Research Site

Los Angeles, California, United States

Research Site

Grand Junction, Colorado, United States

Research Site

Wheat Ridge, Colorado, United States

Research Site

Baltimore, Maryland, United States

Research Site

Detroit, Michigan, United States

Research Site

Chapel Hill, North Carolina, United States

Research Site

Tacoma, Washington, United States

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Hangzhou, China

Research Site

Jinan, China

Research Site

Yantai, China

Research Site

Zhengzhou, China

Research Site

Bois-Guillaume, France

Research Site

Caen, France

Research Site

Créteil, France

Research Site

Dijon, France

Research Site

Montpellier, France

Research Site

Batumi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Athens, Greece

Research Site

Athens, Greece

Research Site

Elaiones, Greece

Research Site

Piraeus, Greece

Research Site

Thessaloniki, Greece

Research Site

Genoa, Italy

Research Site

Meldola, Italy

Research Site

Milan, Italy

Research Site

Naples, Italy

Research Site

Orbassano, Italy

Research Site

Perugia, Italy

Research Site

Rozzano, Italy

Research Site

Udine, Italy

Research Site

Verona, Italy

Research Site

Kuala Lumpur, Malaysia

Research Site

Kuching, Malaysia

Research Site

Perai, Malaysia

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Porto, Portugal

Research Site

Porto, Portugal

Research Site

Cluj-Napoca, Romania

Research Site

Craiova, Romania

Research Site

Floreşti, Romania

Research Site

Belgrade, Serbia

Research Site

Belgrade, Serbia

Research Site

Kamenitz, Serbia

Research Site

Kragujevac, Serbia

Research Site

Seongnam, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Suwon, South Korea

Research Site

A Coruña, Spain

Research Site

Alcorcón, Spain

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Santander, Spain

Research Site

Santiago de Compostela, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Basel, Switzerland

Research Site

Geneva, Switzerland

Research Site

Lausanne, Switzerland

Research Site

Winterthur, Switzerland

Research Site

Zurich, Switzerland

Research Site

Changhua, Taiwan

Research Site

New Taipei City, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan